Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-16 4:05 pm Purchase | 2025-10-08 | 13D | TransCode Therapeutics, Inc. RNAZ | CK Life Sciences Int'l., (Holdings) Inc. | 83,285 9.100% | 83,285 (New Position) | Filing History |
| 2025-08-14 9:55 pm Purchase | 2025-06-30 | 13G | TransCode Therapeutics, Inc. RNAZ | Anson Funds Management LP | 27,125 0.100% | 23,072 (+569.29%) | Filing History |
| 2025-08-14 2:16 pm Purchase | 2025-06-30 | 13G | TransCode Therapeutics, Inc. RNAZ | GOLDMAN SACHS GROUP INC GS | 49,018 5.900% | 49,018 (New Position) | Filing History |
| 2025-03-20 5:16 pm Purchase | 2025-03-07 | 13D | TransCode Therapeutics, Inc. RNAZ | Thomas Joseph Tracy | 1,250 5.000% | 1,250 (New Position) | Filing History |
| 2025-02-14 5:16 pm Purchase | 2024-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | Anson Funds Management LP | 4,053 9.900% | 4,053 (New Position) | Filing History |
| 2025-01-03 7:25 pm Purchase | 2024-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | SABBY MANAGEMENT LLC | 2,484 9.900% | 2,484 (New Position) | Filing History |
| 2024-11-06 4:05 pm Sale | 2024-09-30 | 13G | TransCode Therapeutics, Inc. RNAZ | 3i, LP | 0 0.000% | -1,858 (Position Closed) | Filing History |
| 2024-07-26 4:05 pm Purchase | 2024-07-23 | 13G | TransCode Therapeutics, Inc. RNAZ | 3i, LP | 1,858 9.900% | 1,858 (New Position) | Filing History |
| 2024-06-21 4:02 pm Purchase | 2024-06-14 | 13D | TransCode Therapeutics, Inc. RNAZ | Fitzgerald Thomas A | 457 5.500% | 457 (New Position) | Filing History |
| 2024-02-15 4:00 pm Purchase | 2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | Medarova Zdravka | 121 0.400% | 121 (New Position) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | TANG CAPITAL PARTNERS LP | 0 0.000% | -10 (Position Closed) | Filing History |
| 2024-02-13 8:12 pm Sale | 2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | Lind Global Fund II LP | 28 0.100% | -39 (-57.95%) | Filing History |
| 2023-12-07 4:30 pm Purchase | 2023-12-04 | 13G | TransCode Therapeutics, Inc. RNAZ | Lind Global Fund II LP | 68 9.900% | 68 (New Position) | Filing History |
| 2023-10-10 4:00 pm Purchase | 2023-09-28 | 13D | TransCode Therapeutics, Inc. RNAZ | Dudley Robert Michael | 6 1.900% | 3 (+104.19%) | Filing History |
| 2023-09-26 11:06 am Purchase | 2023-09-26 | 13G | TransCode Therapeutics, Inc. RNAZ | TANG CAPITAL PARTNERS LP | 10 9.990% | 10 (New Position) | Filing History |
| 2023-06-16 4:00 pm Purchase | 2023-06-09 | 13D | TransCode Therapeutics, Inc. RNAZ | Dudley Robert Michael | 3 6.000% | 3 (New Position) | Filing History |
| 2023-02-10 08:00 am Purchase | 2022-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | Medarova Zdravka | 2 12.700% | 0 (+2.61%) | Filing History |
| 2022-12-19 5:36 pm Purchase | 2022-10-01 | 13D | TransCode Therapeutics, Inc. RNAZ | Dudley Robert Michael | 2 12.700% | 0 (+22.54%) | Filing History |
| 2022-12-19 5:33 pm Purchase | 2021-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | Medarova Zdravka | 2 12.500% | 2 (New Position) | Filing History |
| 2022-12-19 5:32 pm Purchase | 2021-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ | Dudley Robert Michael | 2 10.600% | 2 (New Position) | Filing History |